Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
A.P. Pharma, Inc.
A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV
October 17th, 2008
A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced positive results from its pivotal Phase 3 study comparing the efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi(R) for the prevention of chemotherapy induced nausea and vomiting (CINV). Patients in the study were classified into moderately or highly emetogenic chemotherapy levels according to the Hesketh algorithm, which assigns emetogenic levels based on the chemotherapy agent, drug dosage and combinations employed. The Phase 3 trial included 1,395 patients treated at 103 centers in the United States, Poland and India. The results announced represent...
Source: Health Business Week (2008-10-17)
|
